Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07494942 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis

Study acronym: RECARDA
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Jan 30, 2029 → Sep 23, 2029
See other at-risk trials from University Hospital, Montpellier

Record History

  1. Primary and study completion pushed from Jan 30, 2029 to Sep 23, 2029 Recruitment opened · Start date changed from estimate of Dec 30, 2026 to Sep 23, 2026 · Eligibility criteria expanded, about 11 words · 2 more Show 5 more changesShow less
    • Recruitment opened
    • Start date changed from estimate of Dec 30, 2026 to Sep 23, 2026
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 4 of 13 entries
    • Site details revised
  2. Start date: Apr 30, 2026 to Dec 30, 2026v3
  3. Secondary endpoints revised (13)v2 See this version in full on ClinicalTrials.gov ↗
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if a structured cardiac rehabilitation program can help people with cardiac amyloidosis improve their ability to exercise and their quality of life. The main questions it aims to answer are: Does cardiac rehabilitation raise peak oxygen uptake (VO₂ peak), which shows how well the heart and lungs work during exercise? Is cardiac rehabilitation safe and practical for people with cardiac amyloidosis? How does cardiac rehabilitation affect other exercise measures, heart function, symptoms linked to autonomic dysfunction, and quality of life? This study has no comparison group. Researchers will measure each participant's results before and after the rehabilitation program. Participants will: Complete a cardiac rehabilitation program for 5 weeks. Have tests before the program starts and again about 3 months later. These tests include: A cardiopulmonary exercise test A heart function test using electrical impedance A questionnaire about quality of life A blood sample A blood pressure test to check for orthostatic hypotension The study will include adults aged 18 or older with transthyretin cardiac amyloidosis who are able to perform an exercise test.
Trial Details
NCT Number NCT07494942
Lead Sponsor University Hospital, Montpellier
Conditions Amyloidosis
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov